Myriad Genetics (NASDAQ:MYGN) will release its earnings data after the market closes on Tuesday, August 14th. Analysts expect Myriad Genetics to post earnings of $0.33 per share for the quarter.
Myriad Genetics opened at $42.53 on Monday, Marketbeat Ratings reports. The company has a market cap of $3.05 billion, a PE ratio of 40.50, a P/E/G ratio of 2.90 and a beta of 0.49. Myriad Genetics has a 52 week low of $27.22 and a 52 week high of $44.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.16.
Several research firms have recently commented on MYGN. ValuEngine raised Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 24th. Bank of America upped their target price on Myriad Genetics from $20.00 to $31.00 and gave the company an “underperform” rating in a report on Monday, July 16th. Morgan Stanley raised Myriad Genetics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $35.00 to $55.00 in a report on Wednesday, July 11th. TheStreet raised Myriad Genetics from a “c+” rating to a “b” rating in a report on Monday, June 4th. Finally, Zacks Investment Research lowered Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 18th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $36.40.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Further Reading: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.